Headquarters:
South San Francisco, CA
Description:
Portola Pharmaceuticals develops therapeutics for acute and chronic cardiovascular, and autoimmune and inflammatory diseases.
Founders:
Charles Homcy
Categories:
Biotechnology
Website:
http://www.portola.com

Company Details

Update

Portola Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops therapeutics for acute and chronic cardiovascular and autoimmune/inflammatory diseases. The company’s products include PRT054021, an oral factor Xa inhibitor for the prevention and treatment of deep vein thrombosis and pulmonary embolism after orthopedic surgery; for stroke prevention in patients with atrial fibrillation; and for secondary prevention of myocardial infarction and stroke. Its products also include PRT060128, an oral and intravenous ADP receptor antagonist for the treatment of patients with acute coronary syndrome; for the prevention of cardiovascular events in patients undergoing percutaneous coronary intervention; and for secondary prevention of myocardial infarction and stroke. In addition, the company’s products include PRT062607, an oral Syk-specific kinase inhibitor for treating chronic inflammatory diseases and Rheumatoid Arthritis (RA) which is used to treat certain cancers including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Portola Pharmaceuticals, Inc. was founded in 2003 and is based in South San Francisco, California.

Current Team (4)

Update

Past Team (5)

Update

Funding Rounds (3) - $158.1M

Update

Board Members and Advisors (3)

Update

Investors (2)

Update

Offices/Locations (1)

Update
  • Office

    270 E. Grand Avenue

    South San Francisco, CA 94080

    USA